Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposar...( DENVER March 3 /- Pharmatech Inc....),Health

DENVER, March 3 /PRNewswire/ -- Pharmatech, Inc., a Research Management Organization (RMO), has contracted with Systems Medicine LLC (SML), a subsidiary of Seattle-based Cell Therapeutics, Inc. (CTI), to provide research and site management services for their phase II open-label clinical study for patients with myxoid liposarcoma with a (12;16) translocation. The study is intended to assess the safety and efficacy of SML's experimental drug product, brostallicin. The trial will also be supported by the Sarcoma Foundation of America (SFA).

Pharmatech will manage this sarcoma trial using its innovative Just-In-Time(TM) (JIT) approach. This streamlined approach was created to increase enrollment in clinical trials for rare cancer disease indications with narrow patient populations. The study sponsor does not open the trial at the site level until a potential patient is identified through basic standard of care procedures, thus saving time, money, and effort for both the sites and the sponsors. Patient enrollment, through Just-In-Time, is further increased because a protocol can be rolled out to a large number of qualified Research Network sites with minimal expense of time and capital.

The SML trial allowed for the formation of a partnership between Pharmatech and the Sarcoma Foundation of America. The union of the two organizations helps create awareness for the Foundation's Sarcoma Patient Registry program. The Registry allows patients to call into the Foundation to sign up for participation in the Registry program. If they consent, then they are notified by the Foundation if a current or future trial fits their specific disease indications. Matthew Alsante, Executive Director, Sarcoma Foundation of America, states, "The collaboration allows for a superior coordination among key players in the clinical trial process. The patients come to the Foundation through our sophisticated Registry. The Foundation takes the incidence data from the Registry t
'/>"/>